TVTX 株価分析 — Travere Therapeutics Inc (Healthcare >> Biotechnology)
TVTX に関するよくある質問
TVTXのPER(株価収益率)は?
Travere Therapeutics Inc(TVTX)は現在PER 179.80倍で取引されています。
TVTXのROE(自己資本利益率)は?
Travere Therapeutics IncのROEは-21.70%です。
TVTXの配当利回りは?
Travere Therapeutics Incの配当利回りは0.00%です。
TVTXの品質スコア(Quality Score)は?
当社のAIはTVTXの総合財務品質を100点中54点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
TVTXは今が買い時ですか?
当社AIのタイミングスコアは100点中67点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
TVTXはどのセクターに属しますか?
Travere Therapeutics IncはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
TVTX AI Analysis Summary
Our AI summary for TVTX: Travere Therapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 179.80, ROE of -21.70%, a dividend yield of 0.00%. Its financial Quality Score stands at 54/100 — mid-range fundamentals relative to the market. The AI Timing Score is 67/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 56.02
Price
1.04
(1.89%)
Day Change
|
|
|---|
TVTX, ファンダメンタルスコアはnot quite good ( ファンダメンタル = 54) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
平均ROEが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 56.02 |
| PBV / Sector |
51.79 / 44,022.72
|
| Earning Per Share | -0.23 |
| PE / Sector |
179.80 / 19.17
|
| PEG or PE/Growth / Sector |
41.15 / 1.24
|
| Average 1M Daily Value |
72.49 M
|
| Average 1W Daily Value |
89.00 M
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
52% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:59 |
| Symbol | TVTX |
| Name | TRAVERE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 92.99 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 5,112.75 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 3611 Valley Centre Drive, San Diego, CA, United States, 92130
Phone: 888 969 7879
Website: https://travere.com
Employees: 497
Sector: Healthcare >> Biotechnology
Description: Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google